Leirika Ngangom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Leirika Ngangom has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Shabaaz Begum Jameel Pasha
Department of Microbiology, Graphic Era (Deemed to be University), Dehradun, India
3 shared publications - Divya Venugopal
Department of Microbiology, Graphic Era (Deemed to be University), Dehradun, India
2 shared publications - Neha Pandey
Department of Biotechnology, Graphic Era (Deemed to be University), Dehradun, India
2 shared publications - Ashim Gupta
Future Biologics, Lawrenceville, GA 30043, USA
1 shared publication - Divya Korappara Venugopal
Graphic Era (Deemed to be University)
1 shared publication Divya Venugopal
1 shared publication
Latest Publications
- Open Access
- 24 October 2025
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 26 (1) , 1-13
Green synthesis, characterization and antibacterial potential of zinc oxide nanoparticles with naringenin
In comparison to physical and chemical fabrication of metal nanoparticles, green synthesized nanoparticles are non-toxic, biocompatible, and biodegradable; they undergo a single-step bioreduction process. This research was primarily driven by the goal of creating an environment friendly, efficient, and sustainable process for synthesizing ZnO NPs using naringenin, a naturally occurring flavonoid with well-established medicinal benefits. The growing need to replace traditional chemical synthesis methods which frequently involve energy-intensive processes and toxic reducing agents with environment friendly, biocompatible, and scalable alternatives served as the impetus for the study. The synthesized ZnO NPs were characterized using different analytical techniques such as UV-Vis, FTIR, XRD, FESEM-EDS and HRTEM. The UV-Vis spectra of the synthesized zinc oxide nanoparticles showed a strong absorption peak at 374 nm. The XRD pattern exhibits prominent and precise diffraction, which indicate good crystallinity. Both FESEM and HRTEM confirmed that the synthesized ZnO NPs were compactly organized and polycrystalline-looking particles with an average size 25 to 31 nm. EDS analysis provided further evidence of the product’s purity. Disc diffusion method was used to examined the antibacterial potential of the synthesized ZnO NPs against pathogenic bacterial strains namely S. aureus, P. aeruginosa, K. pneumoniae, and E. faecalis. The zones of inhibition of 11 ± 0.1 mm, 10 ± 0.1 mm, 9 ± 0.1 mm and 9 ± 0.1 mm was observed in E. faecalis, K. pneumoniae, P. aeruginosa, and S. aureus respectively.
- 24 October 2025
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 26 (1) , 1-13
Open AccessGreen synthesis, characterization and antibacterial potential of zinc oxide nanoparticles with naringenin
In comparison to physical and chemical fabrication of metal nanoparticles, green synthesized nanoparticles are non-toxic, biocompatible, and biodegradable; they undergo a single-step bioreduction process. This research was primarily driven by the goal of creating an environment friendly, efficient, and sustainable process for synthesizing ZnO NPs using naringenin, a naturally occurring flavonoid with well-established medicinal benefits. The growing need to replace traditional chemical synthesis methods which frequently involve energy-intensive processes and toxic reducing agents with environment friendly, biocompatible, and scalable alternatives served as the impetus for the study. The synthesized ZnO NPs were characterized using different analytical techniques such as UV-Vis, FTIR, XRD, FESEM-EDS and HRTEM. The UV-Vis spectra of the synthesized zinc oxide nanoparticles showed a strong absorption peak at 374 nm. The XRD pattern exhibits prominent and precise diffraction, which indicate good crystallinity. Both FESEM and HRTEM confirmed that the synthesized ZnO NPs were compactly organized and polycrystalline-looking particles with an average size 25 to 31 nm. EDS analysis provided further evidence of the product’s purity. Disc diffusion method was used to examined the antibacterial potential of the synthesized ZnO NPs against pathogenic bacterial strains namely S. aureus, P. aeruginosa, K. pneumoniae, and E. faecalis. The zones of inhibition of 11 ± 0.1 mm, 10 ± 0.1 mm, 9 ± 0.1 mm and 9 ± 0.1 mm was observed in E. faecalis, K. pneumoniae, P. aeruginosa, and S. aureus respectively.
- 2 April 2024
- Published by Springer Nature
- p. 235-247
Nanotechnology in Food Crop Production and Food Processing Industry
- 2 April 2024
- Published by Springer Nature
- p. 235-247
Nanotechnology in Food Crop Production and Food Processing Industry
- 4 January 2024
- Published by Taylor & Francis in Natural Product Research
- Vol. 38 (24) , 4468-4478
Investigation of Trifolium repens L. from the Indian Himalayan region as a phyto-therapeutic agent
Trifolium repens is a well-known herbaceous, perennial herb and has been extensively used in the traditional medicine system over the years. Various parts of the plant are traditionally used as a curative agent against several health ailments such as skin problems, wound healing, stomach disorders, sedative, fever, antiseptic, analgesic, expectorant, psoriasis and eczema. To maximise the plant's potential for usage in the future, the review also aims to update information about its significant pharmacological properties. The ethnomedicinal benefits of T. repens have been well studied; however, the facets of the plant have not been explored yet. The current review outlines several bioactive compounds quantified from T. repens and a few of them namely quercetin, kaempferol, myricetin, acacetin and linamarin, have been reported to have biological activities such as antibacterial, antifungal, antileishmanial, anti-inflammatory, antiaging and anti-hepatotoxic activities. A significant number of in vitro studies have been done on the plant extract, but little is known about the isolation and efficacy of the potent natural bioactive compounds of T. repens. The bioactive compounds in T. repens can be used for advanced drug development against various health disorders. [GRAPHICS]
- 4 January 2024
- Published by Taylor & Francis in Natural Product Research
- Vol. 38 (24) , 4468-4478
Investigation of Trifolium repens L. from the Indian Himalayan region as a phyto-therapeutic agent
Trifolium repens is a well-known herbaceous, perennial herb and has been extensively used in the traditional medicine system over the years. Various parts of the plant are traditionally used as a curative agent against several health ailments such as skin problems, wound healing, stomach disorders, sedative, fever, antiseptic, analgesic, expectorant, psoriasis and eczema. To maximise the plant's potential for usage in the future, the review also aims to update information about its significant pharmacological properties. The ethnomedicinal benefits of T. repens have been well studied; however, the facets of the plant have not been explored yet. The current review outlines several bioactive compounds quantified from T. repens and a few of them namely quercetin, kaempferol, myricetin, acacetin and linamarin, have been reported to have biological activities such as antibacterial, antifungal, antileishmanial, anti-inflammatory, antiaging and anti-hepatotoxic activities. A significant number of in vitro studies have been done on the plant extract, but little is known about the isolation and efficacy of the potent natural bioactive compounds of T. repens. The bioactive compounds in T. repens can be used for advanced drug development against various health disorders. [GRAPHICS]
- 7 February 2023
- Published by Springer Nature in Human Cell
- Vol. 36 (3) , 877-893
Emergence of monkeypox: a worldwide public health crisis
The human monkeypox virus (MPV), a zoonotic illness that was hitherto solely prevalent in Central and West Africa, has lately been discovered to infect people all over the world and has become a major threat to global health. Humans unintentionally contract this zoonotic orthopoxvirus, which resembles smallpox, when they come into contact with infected animals. Studies show that the illness can also be transferred through frequent proximity, respiratory droplets, and household linens such as towels and bedding. However, MPV infection does not presently have a specified therapy. Smallpox vaccinations provide cross-protection against MPV because of antigenic similarities. Despite scant knowledge of the genesis, epidemiology, and ecology of the illness, the incidence and geographic distribution of monkeypox outbreaks have grown recently. Polymerase chain reaction technique on lesion specimens can be used to detect MPV. Vaccines like ACAM2000, vaccinia immune globulin intravenous (VIG-IV), and JYNNEOS (brand name: Imvamune or Imvanex) as well as FDA-approved antiviral medications such as brincidofovir (brand name: Tembexa), tecovirimat (brand name: TPOXX or ST-246), and cidofovir (brand name: Vistide) are used as therapeutic medications against MPV. In this overview, we provide an outline of the MPV’s morphology, evolution, mechanism, transmission, diagnosis, preventative measures, and therapeutic approaches. This study offers the fundamental information required to prevent and manage any further spread of this emerging virus.
- 7 February 2023
- Published by Springer Nature in Human Cell
- Vol. 36 (3) , 877-893
Emergence of monkeypox: a worldwide public health crisis
The human monkeypox virus (MPV), a zoonotic illness that was hitherto solely prevalent in Central and West Africa, has lately been discovered to infect people all over the world and has become a major threat to global health. Humans unintentionally contract this zoonotic orthopoxvirus, which resembles smallpox, when they come into contact with infected animals. Studies show that the illness can also be transferred through frequent proximity, respiratory droplets, and household linens such as towels and bedding. However, MPV infection does not presently have a specified therapy. Smallpox vaccinations provide cross-protection against MPV because of antigenic similarities. Despite scant knowledge of the genesis, epidemiology, and ecology of the illness, the incidence and geographic distribution of monkeypox outbreaks have grown recently. Polymerase chain reaction technique on lesion specimens can be used to detect MPV. Vaccines like ACAM2000, vaccinia immune globulin intravenous (VIG-IV), and JYNNEOS (brand name: Imvamune or Imvanex) as well as FDA-approved antiviral medications such as brincidofovir (brand name: Tembexa), tecovirimat (brand name: TPOXX or ST-246), and cidofovir (brand name: Vistide) are used as therapeutic medications against MPV. In this overview, we provide an outline of the MPV’s morphology, evolution, mechanism, transmission, diagnosis, preventative measures, and therapeutic approaches. This study offers the fundamental information required to prevent and manage any further spread of this emerging virus.
- 15 October 2022
- Published by Elsevier in Materials Today: Proceedings
- Vol. 73, 142-150
In-silico screening and identification of potential bioactive compounds of Trifolium repens against pathogenic bacterial target proteins
- 15 October 2022
- Published by Elsevier in Materials Today: Proceedings
- Vol. 73, 142-150
In-silico screening and identification of potential bioactive compounds of Trifolium repens against pathogenic bacterial target proteins